Rebuttal from Dr van Meerbeeck

Por van Meerbeeck, Jan P.
Publicado no Transl Lung Cancer Res (2015)

Rebuttal from Dr Nestle and Dr Belderbos

Por Nestle, Ursula, Belderbos, José
Publicado no Transl Lung Cancer Res (2015)

Rebuttal from Ms Woodford and Dr Senthi

Por Woodford, Katrina, Senthi, Sashendra
Publicado no Transl Lung Cancer Res (2015)

Rebuttal from Prof. Kong and Dr. Rabatic

Por Rabatic, Bryan M., Kong, Feng-Ming (Spring)
Publicado no Transl Lung Cancer Res (2016)

Cons: Can liquid biopsy replace tissue biopsy?—the US experience

Por Mino-Kenudson, Mari
Publicado no Transl Lung Cancer Res (2016)

Pros: Can tissue biopsy be replaced by liquid biopsy?

Por Ilié, Marius, Hofman, Paul
Publicado no Transl Lung Cancer Res (2016)

What is better/reliable, mitosis counting or Ki67/MIB1 staining?

Por Kriegsmann, Mark, Warth, Arne
Publicado no Transl Lung Cancer Res (2016)

Gene alterations, smoking and histology: when the deeper means the rarer

Por Stella, Giulia M.
Publicado no Transl Lung Cancer Res (2013)

Cons: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with inoperable large volume stage III non-small cell lung cancer

Por Rodrigues, George
Publicado no Transl Lung Cancer Res (2016)

Cons: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Por Decaluwé, Herbert, Dooms, Christophe
Publicado no Transl Lung Cancer Res (2016)

Pros: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Por Obiols, Carme, Call, Sergi
Publicado no Transl Lung Cancer Res (2016)

Pros: long-term CT scan follow-up should be the standard of care in patients who are curatively treated for an early-stage non-small cell lung cancer

Por Hanna, Waël C.
Publicado no Transl Lung Cancer Res (2015)

Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer

Por van Meerbeeck, Jan P., Sirimsi, Halil
Publicado no Transl Lung Cancer Res (2015)

Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung...

Por Giuliani, Meredith, Bezjak, Andrea
Publicado no Transl Lung Cancer Res (2016)

Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Por Nestle, Ursula, Belderbos, José
Publicado no Transl Lung Cancer Res (2015)

Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Por Woodford, Katrina, Senthi, Sashendra
Publicado no Transl Lung Cancer Res (2015)

Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung...

Por Nguyen, Timothy K., Palma, David A.
Publicado no Transl Lung Cancer Res (2016)

Immunotherapy meets targeted therapy: will this team end the war against cancer?

Por Morales-Espinosa, Daniela, García-Román, Silvia, Teixidó, Cristina, Karachaliou, Niki, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Endothelial Dll4-Notch signaling in tumor microenvironment: is there any hidden therapeutic opportunity?

Por Kumar, Amit, Desai, Sejal, Pandey, Badri N.
Publicado no Transl Lung Cancer Res (2013)

Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer

Por Rabatic, Bryan M., Kong, Feng-Ming (Spring)
Publicado no Transl Lung Cancer Res (2016)